Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccinex Inc (NQ: VCNX )

0.4735 +0.0135 (+2.93%)
Streaming Delayed Price Updated: 1:50 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 158,500
Open 0.4700
Bid (Size) 0.4651 (4)
Ask (Size) 0.4800 (201)
Prev. Close 0.4600
Today's Range 0.4600 - 0.4800
52wk Range 0.3400 - 1.500
Shares Outstanding 54,856,369
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
From Vaccinex, Inc.
Via GlobeNewswire
Earnings Scheduled For May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter. 
Via Benzinga

Performance

YTD
-25.09%
-25.09%
1 Month
+33.87%
+33.87%
3 Month
-1.35%
-1.35%
6 Month
-35.60%
-35.60%
1 Year
-63.29%
-63.29%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Private Placement with Commitments of $5.0 Million
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
From Vaccinex, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
From Vaccinex, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MarketBeat Week in Review – 2/6 - 2/10
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Should Investors Buy or Sell the Vaccinex Patent News?
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Via InvestorPlace
Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today?
Via InvestorPlace
Why Is Oak Street Health (OSH) Stock Up 36% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.